Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blocka...
12 4월 2018 - 8:00PM
PRESS RELEASE
Lund, April 12, 2018 - Active
Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner
NeoTX Therapeutics Ltd. will present new data for ANYARA
(Naptumumab Estafenatox) at the Annual Meeting of the American
Association for Cancer Research (AACR) in Chicago on April 14-18,
2018. The poster Naptumumab Estafenatox Induces T
cells Tumor Recognition, Turning anti-PD1 Unresponsive "Cold"
Tumors into "Hot" Responsive Tumors will be presented between
1:00 p.m. and 5:00 p.m. local time on April 16, 2018, at the
session "Immune Checkpoints 2". The data to be presented
demonstrates a synergistic anti-tumor effect when ANYARA is
combined with a PD-1 checkpoint inhibitor in several different
tumor models that are marginally responsive to
PD-1 inhibition.
Checkpoint inhibitors are drugs that unleash an
immune system attack against tumor cells. It is well established
that a key factor that limits the effectiveness of checkpoint
inhibition is tumor recognition. ANYARA is a Tumor Targeted
Superantigen (TTS) that enhances the ability of the immune system
to recognize and kill the tumors and is therefore attractive for
combination therapy to enhance the efficacy of checkpoint
inhibition.
"We are enthusiastic that our partner NeoTX has
been selected to present these important data showing that ANYARA,
through its tumor-targeted mode of action, enhances the effect of
PD-1 inhibition and thereby potentially increases the clinical
benefit of such treatment in the long term," says Helén
Tuvesson, CEO of Active Biotech.
A summary of the poster presentation will be published at:
http://www.abstractsonline.com/pp8/#!/4562/presentation/9330
About ANYARA
ANYARA is a Tumor Targeting Superantigen (TTS)
that enhances the ability of the immune system to recognize and
kill tumors. Active Biotech has an agreement with NeoTX
Therapeutics Ltd since October 2016 for the global development and
commercialization of ANYARA for the treatment of cancer.
Clinically, the development of ANYARA has focused on cancer forms
with a high medical need. Positive data was reported from clinical
Phase 1 and 2/3 studies in lung cancer, renal cell cancer and
pancreatic cancer, where ANYARA was studied both as a single agent
and in combination with an established tumor therapy in patients
with advanced cancer. Preparations for a clinical trial in
combination with a checkpoint inhibitor are ongoing.
Lund, April 12, 2018
Active Biotech AB (publ)
For further information, please
contact:
Helén Tuvesson, CEO
Tel. +46 46 19 20 95
Email: helen.tuvesson@activebiotech.com
Hans Kolam, CFO
Tel. +46 46 19 20 44
Email: hans.kolam@activebiotech.com
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties is in development for neurodegenerative
diseases in partnership with Teva Pharmaceutical Industries Ltd.
ANYARA, an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more
information.
NeoTX Therapeutics Ltd. is
based in Rehovot, Israel, and is a specialty biopharmaceutical
company, with a focus on research and development in oncology
immunotherapy. NeoTX was founded with the aim of offering cancer
patients safe and effective immunotherapies. Please visit
www.neotx.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
This information
was submitted for publication, through the agency of the contact
person set out above, at 13.00 p.m. CET on April 12, 2018.
Active Biotech's partner NeoTX
presents new data at AACR
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024